Multi-analytical platform metabolomic approach to study miltefosine mechanism of action and resistance in Leishmania

Analytical and Bioanalytical Chemistry

Volumn 406, Issue 14, 2014, Pages 3459-3476

  Canuto, Gisele A B ^a,b   Castilho Martins, Emerson A ^a,c   Tavares, Marina F M ^b   Rivas, Luis ^d   Barbas, Coral ^a   López Gonzálvez, Ángeles ^a  

^a Centro de Metabolómica y Bioanálisis CEMBIO Unidad Metabolómica Interacciones y Bioanálisis UMIB Campus Monteprincipe   (Spain)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF AMAPÁ   (Brazil)

^d CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Drug action; Leishmania (L.) donovani; Mass spectrometry; Metabolic fingerprinting; Miltefosine; Resistance

Indexed keywords

AMINO ACIDS; CAPILLARY ELECTROPHORESIS; ELECTRIC RESISTANCE; GAS CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM;

DRUG ACTION; LEISHMANIA; MECHANISM OF ACTION; METABOLIC CHANGES; METABOLIC FINGERPRINTING; MILTEFOSINE; POLYAMINE METABOLISM; REACTIVE OXYGEN SPECIES;

DRUG PRODUCTS;

ARGININE; CARBON; GLUTATHIONE; MILTEFOSINE; PHOSPHORYLCHOLINE; REACTIVE OXYGEN METABOLITE; SPERMIDINE; TRYPANOTHIONE;

ANALOGS AND DERIVATIVES; CAPILLARY ELECTROPHORESIS; CHEMISTRY; DRUG RESISTANCE; GAS CHROMATOGRAPHY; HYDRODYNAMICS; LEISHMANIA DONOVANI; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLISM; METABOLOMICS; QUALITY CONTROL;

ARGININE; CARBON; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, LIQUID; DRUG RESISTANCE; ELECTROPHORESIS, CAPILLARY; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLUTATHIONE; HYDRODYNAMICS; LEISHMANIA DONOVANI; MASS SPECTROMETRY; METABOLOMICS; PHOSPHORYLCHOLINE; QUALITY CONTROL; REACTIVE OXYGEN SPECIES; SPERMIDINE;

EID: 84901421544     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-014-7772-1     Document Type: Article

References (90)

1. Organization WH Technical report series no. 949. In: Control of the leishmaniasis: report of a meeting of the World Health Organization Expert Committee on the Control of Leishmaniases, Geneva, 2010. pp 22-26
2. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, Team WLC (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7(5):e35671
3. Alvar J, Croft SL, Kaye P, Khamesipour A, Sundar S, Reed SG (2013) Case study for a vaccine against leishmaniasis. Vaccine 31(Suppl 2):B244-B249
4. Nagill R, Kaur S (2011) Vaccine candidates for leishmaniasis: a review. Int Immunopharmacol 11(10):1464-1488
5. Croft SL, Olliaro P (2011) Leishmaniasis chemotherapy-challenges and opportunities. Clin Microbiol Infect 17(10):1478-1483
6. van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M (2010) Combination therapy for visceral leishmaniasis. Lancet Infect Dis 10(3):184-194
7. Sundar S, Chakravarty J (2013) Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother 14(1):53-63
8. Alvar J, Yactayo S, Bern C (2006) Leishmaniasis and poverty. Trends Parasitol 22(12):552-557 (Pubitemid 44716723)
9. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347(22):1739-1746 (Pubitemid 35375612)
10. Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ (2012) Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 67(11):2576-2597
11. Kumar D, Kulshrestha A, Singh R, Salotra P (2009) In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob Agents Chemother 53(2):835-838
12. Moreira W, Leprohon P, Ouellette M (2011) Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania. Cell Death Dis 2:e201
13. Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TP, Beijnen JH, Vanaerschot M, Decuypere S, Dhakal SS, Das ML, Karki P, Singh R, Boelaert M, Dujardin JC (2013) Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis 56(11):1530-1538
14. Sundar S, Chakravarty J (2012) Recent advances in the diagnosis and treatment of kala-azar. Natl Med J India 25(2):85-89
15. Paris C, Loiseau PM, Bories C, Bréard J (2004) Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 48(3):852-859 (Pubitemid 38280335)
16. Proto WR, Coombs GH, Mottram JC (2013) Cell death in parasitic protozoa: regulated or incidental? Nat Rev Microbiol 11(1):58-66
17. Saugar JM, Delgado J, Hornillos V, Luque-Ortega JR, Amat-Guerri F, Acuña AU, Rivas L (2007) Synthesis and biological evaluation of fluorescent leishmanicidal analogues of hexadecylphosphocholine (miltefosine) as probes of antiparasite mechanisms. J Med Chem 50(24):5994-6003
18. Zufferey R, Mamoun CB (2002) Choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs. Mol Biochem Parasitol 125(1-2):127-134 (Pubitemid 35449252)
19. Lux H, Heise N, Klenner T, Hart D, Opperdoes FR (2000) Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol Biochem Parasitol 111(1):1-14
20. Barratt G, Saint-Pierre-Chazalet M, Loiseau PM (2009) Cellular transport and lipid interactions of miltefosine. Curr Drug Metab 10(3):247-255
21. Imbert L, Ramos RG, Libong D, Abreu S, Loiseau PM, Chaminade P (2012) Identification of phospholipid species affected by miltefosine action in Leishmania donovani cultures using LC-ELSD, LC-ESI/MS, and multivariate data analysis. Anal Bioanal Chem 402(3):1169-1182
22. Rakotomanga M, Saint-Pierre-Chazalet M, Loiseau PM (2005) Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions. Antimicrob Agents Chemother 49(7):2677-2686 (Pubitemid 40917578)
23. Getachew F, Gedamu L (2012) Leishmania donovani mitochondrial iron superoxide dismutase A is released into the cytosol during miltefosine induced programmed cell death. Mol Biochem Parasitol 183(1):42-51
24. Luque-Ortega JR, Rivas L (2007) Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes. Antimicrob Agents Chemother 51(4):1327-1332 (Pubitemid 46586813)
25. Zuo X, Djordjevic JT, Bijosono Oei J, Desmarini D, Schibeci SD, Jolliffe KA, Sorrell TC (2011) Miltefosine induces apoptosis-like cell death in yeast via Cox9p in cytochrome c oxidase. Mol Pharmacol 80(3):476-485
26. Das M, Saudagar P, Sundar S, Dubey VK (2013) Miltefosine-unresponsive Leishmania donovani has a greater ability than miltefosine-responsive L. donovani to resist reactive oxygen species. FEBS J 280(19):4807-4815
27. Mishra J, Singh S (2013) Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death. Exp Parasitol 135(2):397-406
28. Pérez-Victoria FJ, Gamarro F, Ouellette M, Castanys S (2003) Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem 278(50):49965-49971 (Pubitemid 37548832)
29. Pérez-Victoria FJ, Castanys S, Gamarro F (2003) Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob Agents Chemother 47(8):2397-2403 (Pubitemid 36919436)
30. Pérez-Victoria FJ, Sánchez-Cañete MP, Castanys S, Gamarro F (2006) Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. J Biol Chem 281(33):23766-23775 (Pubitemid 44274152)
31. Sánchez-Cañete MP, Carvalho L, Pérez-Victoria FJ, Gamarro F, Castanys S (2009) Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug. Antimicrob Agents Chemother 53(4):1305-1313
32. Castanys-Muñoz E, Pérez-Victoria JM, Gamarro F, Castanys S (2008) Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement. Antimicrob Agents Chemother 52(10):3573-3579
33. Pérez-Victoria JM, Pérez-Victoria FJ, Parodi-Talice A, Jiménez IA, Ravelo AG, Castanys S, Gamarro F (2001) Alkyl- lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob Agents Chemother 45(9):2468-2474 (Pubitemid 32801897)
34. Coelho AC, Boisvert S, Mukherjee A, Leprohon P, Corbeil J, Ouellette M (2012) Multiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencing. PLoS Negl Trop Dis 6(2):e1512
35. Cojean S, Houzé S, Haouchine D, Huteau F, Lariven S, Hubert V, Michard F, Bories C, Pratlong F, Le Bras J, Loiseau PM, Matheron S (2012) Leishmania resistance to miltefosine associated with genetic marker. Emerg Infect Dis 18(4):704-706
36. Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC, Salotra P (2012) Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis 6(5):e1657
37. García-Hernández R, Manzano JI, Castanys S, Gamarro F (2012) Leishmania donovani develops resistance to drug combinations. PLoS Negl Trop Dis 6(12):e1974
38. Xiayan L, Legido-Quigley C (2008) Advances in separation science applied to metabonomics. Electrophoresis 29(18):3724-3736
39. Smolinska A, Blanchet L, Buydens LM, Wijmenga SS (2012) NMR and pattern recognition methods in metabolomics: from data acquisition to biomarker discovery: a review. Anal Chim Acta 750:82-97
40. Barding GA, Salditos R, Larive CK (2012) Quantitative NMR for bioanalysis and metabolomics. Anal Bioanal Chem 404(4):1165-1179
41. Putri SP, Yamamoto S, Tsugawa H, Fukusaki E (2013) Current metabolomics: technological advances. J Biosci Bioeng 116(1):9-16
42. Barbas C, Moraes EP, Villaseñor A (2011) Capillary electrophoresis as a metabolomics tool for non-targeted fingerprinting of biological samples. J Pharm Biomed Anal 55(4):823-831
43. Rojo D, Barbas C, Rupérez FJ (2012) LC-MS metabolomics of polar compounds. Bioanalysis 4(10):1235-1243
44. Koek MM, Jellema RH, van der Greef J, Tas AC, Hankemeier T (2011) Quantitative metabolomics based on gas chromatography mass spectrometry: status and perspectives. Metabolomics 7(3):307-328
45. Creek DJ, Jankevics A, Breitling R, Watson DG, Barrett MP, Burgess KE (2011) Toward global metabolomics analysis with hydrophilic interaction liquid chromatography-mass spectrometry: improved metabolite identification by retention time prediction. Anal Chem 83(22):8703-8710
46. Requena JM (2011) Lights and shadows on gene organization and regulation of gene expression in Leishmania. Front Biosci (Landmark Ed) 16:2069-2085
47. Chawla B, Jhingran A, Panigrahi A, Stuart KD, Madhubala R (2011) Paromomycin affects translation and vesicle-mediated trafficking as revealed by proteomics of paromomycin -susceptible -resistant Leishmania donovani. PLoS One 6(10):e26660
48. Paape D, Aebischer T (2011) Contribution of proteomics of Leishmania spp. to the understanding of differentiation, drug resistance mechanisms, vaccine and drug development. J Proteomics 74(9):1614-1624
49. Vergnes B, Gourbal B, Girard I, Sundar S, Drummelsmith J, Ouellette M (2007) A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol Cell Proteomics 6(1):88-101 (Pubitemid 46152694)
50. Doyle MA, MacRae JI, De Souza DP, Saunders EC, McConville MJ, Likić VA (2009) LeishCyc: a biochemical pathways database for Leishmania major. BMC Syst Biol 3:57
51. Creek DJ, Anderson J, McConville MJ, Barrett MP (2012) Metabolomic analysis of trypanosomatid protozoa. Mol Biochem Parasitol 181(2):73-84
52. McConville MJ, Naderer T (2011) Metabolic pathways required for the intracellular survival of Leishmania. Annu Rev Microbiol 65:543-561
53. Opperdoes FR, Coombs GH (2007) Metabolism of Leishmania: proven and predicted. Trends Parasitol 23(4):149-158 (Pubitemid 46428624)
54. Scheltema RA, Decuypere S, T'kindt R, Dujardin JC, Coombs GH, Breitling R (2010) The potential of metabolomics for Leishmania research in the post-genomics era. Parasitology 137(9):1291-1302
55. Lamour SD, Choi BS, Keun HC, Müller I, Saric J (2012) Metabolic characterization of Leishmania major infection in activated and nonactivated macrophages. J Proteome Res 11(8):4211-4222
56. Canuto GA, Castilho-Martins EA, Tavares M, López-Gonzálvez A, Rivas L, Barbas C (2012) CE-ESI-MS metabolic fingerprinting of Leishmania resistance to antimony treatment. Electrophoresis 33(12):1901-1910
57. T'Kindt R, Scheltema RA, Jankevics A, Brunker K, Rijal S, Dujardin JC, Breitling R, Watson DG, Coombs GH, Decuypere S (2010) Metabolomics to unveil and understand phenotypic diversity between pathogen populations. PLoS Negl Trop Dis 4(11):e904
58. Seifert K, Matu S, Javier Pérez-Victoria F, Castanys S, Gamarro F, Croft SL (2003) Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 22(4):380-387 (Pubitemid 37163727)
59. Suhre K, Schmitt-Kopplin P (2008) MassTRIX: mass translator into pathways. Nucleic Acids Res 36 (Web Server issue):W481-484.
60. Jiménez-López JM, Ríos-Marco P, Marco C, Segovia JL, Carrasco MP (2010) Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids. Lipids Health Dis 9:33
61. Verma NK, Dey CS (2004) Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Chemother 48(8):3010-3015 (Pubitemid 38992329)
62. Rakotomanga M, Blanc S, Gaudin K, Chaminade P, Loiseau PM (2007) Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob Agents Chemother 51(4):1425-1430 (Pubitemid 46586825)
63. Ramos RG, Libong D, Rakotomanga M, Gaudin K, Loiseau PM, Chaminade P (2008) Comparison between charged aerosol detection and light scattering detection for the analysis of Leishmania membrane phospholipids. J Chromatogr A 1209(1-2):88-94
64. Geilen CC, Wieder T, Orfanos CE (1996) Phosphatidylcholine biosynthesis as a target for phospholipid analogues. Adv Exp Med Biol 416:333-336 (Pubitemid 126727524)
65. Seifert K, Pérez-Victoria FJ, Stettler M, Sánchez- Cañete MP, Castanys S, Gamarro F, Croft SL (2007) Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents 30(3):229-235 (Pubitemid 47135625)
66. T'Kindt R, Jankevics A, Scheltema RA, Zheng L, Watson DG, Dujardin JC, Breitling R, Coombs GH, Decuypere S (2010) Towards an unbiased metabolic profiling of protozoan parasites: optimisation of a Leishmania sampling protocol for HILIC-orbitrap analysis. Anal Bioanal Chem 398(5):2059-2069
67. Krauth-Siegel RL, Bauer H, Schirmer RH (2005) Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew Chem Int Ed Engl 44(5):690-715 (Pubitemid 40203977)
68. Fyfe PK, Westrop GD, Silva AM, Coombs GH, Hunter WN (2012) Leishmania TDR1 structure, a unique trimeric glutathione transferase capable of deglutathionylation and antimonial prodrug activation. Proc Natl Acad Sci U S A 109(29):11693-11698
69. Wyllie S, Cunningham ML, Fairlamb AH (2004) Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem 279(38):39925-39932 (Pubitemid 39258265)
70. Darlyuk I, Goldman A, Roberts SC, Ullman B, Rentsch D, Zilberstein D (2009) Arginine homeostasis and transport in the human pathogen Leishmania donovani. J Biol Chem 284(30):19800-19807
71. Castilho-Martins EA, Laranjeira da Silva MF, dos Santos MG, Muxel SM, Floeter-Winter LM (2011) Axenic Leishmania amazonensis promastigotes sense both the external and internal arginine pool distinctly regulating the two transporter-coding genes. PLoS One 6(11):e27818
72. Basu NK, Kole L, Ghosh A, Das PK (1997) Isolation of a nitric oxide synthase from the protozoan parasite, Leishmania donovani. FEMS Microbiol Lett 156(1):43-47 (Pubitemid 28091832)
73. Genestra M, de Souza WJ, Cysne-Finkelstein L, Leon LL (2003) Comparative analysis of the nitric oxide production by Leishmania sp. Med Microbiol Immunol 192(4):217-223 (Pubitemid 37491682)
74. Saunders EC, Ng WW, Chambers JM, Ng M, Naderer T, Krömer JO, Likic VA, McConville MJ (2011) Isotopomer profiling of Leishmania mexicana promastigotes reveals important roles for succinate fermentation and aspartate uptake in tricarboxylic acid cycle (TCA) anaplerosis, glutamate synthesis, and growth. J Biol Chem 286(31):27706-27717
75. Inbar E, Canepa GE, Carrillo C, Glaser F, Suter Grotemeyer M, Rentsch D, Zilberstein D, Pereira CA (2012) Lysine transporters in human trypanosomatid pathogens. Amino Acids 42(1):347-360
76. Simon MW, Mukkada AJ (1977) Leishmania tropica: regulation and specificity of the methionine transport system in promastigotes. Exp Parasitol 42(1):97-105 (Pubitemid 8118194)
77. Paes LS, Galvez Rojas RL, Daliry A, Floeter-Winter LM, Ramirez MI, Silber AM (2008) Active transport of glutamate in Leishmania (Leishmania) amazonensis. J Eukaryot Microbiol 55(5):382-387
78. Michels PA, Bringaud F, Herman M, Hannaert V (2006) Metabolic functions of glycosomes in trypanosomatids. Biochim Biophys Acta 1763(12):1463-1477 (Pubitemid 44880465)
79. Ginger ML, Chance ML, Sadler IH, Goad LJ (2001) The biosynthetic incorporation of the intact leucine skeleton into sterol by the trypanosomatid Leishmania mexicana. J Biol Chem 276(15):11674-11682
80. Alloatti A, Uttaro AD (2011) Highly specific methyl-end fatty-acid desaturases of trypanosomatids. Mol Biochem Parasitol 175(2):126-132
81. Inbar E, Schlisselberg D, Suter Grotemeyer M, Rentsch D, Zilberstein D (2013) A versatile proline/alanine transporter in the unicellular pathogen Leishmania donovani regulates amino acid homoeostasis and osmotic stress responses. Biochem J 449(2):555-566
82. Weingärtner A, Drobot B, Herrmann A, Sánchez-Cañete MP, Gamarro F, Castanys S, Günther Pomorski T (2010) Disruption of the lipid-transporting LdMT-LdRos3 complex in Leishmania donovani affects membrane lipid asymmetry but not host cell invasion. PLoS One 5(8):e12443
83. Naderer T, McConville MJ (2011) Intracellular growth and pathogenesis of Leishmania parasites. Essays Biochem 51:81-95
84. Haas A (2007) The phagosome: compartment with a license to kill. Traffic 8(4):311-330 (Pubitemid 46421614)
85. Verma S, Mehta A, Shaha C (2011) CYP5122A1, a novel cytochrome P450 is essential for survival of Leishmania donovani. PLoS One 6(9):e25273
86. Reguera RM, Balaña-Fouce R, Showalter M, Hickerson S, Beverley SM (2009) Leishmania major lacking arginase (ARG) are auxotrophic for polyamines but retain infectivity to susceptible BALB/c mice. Mol Biochem Parasitol 165(1):48-56
87. Rosenzweig D, Smith D, Opperdoes F, Stern S, Olafson RW, Zilberstein D (2008) Retooling Leishmania metabolism: from sand fly gut to human macrophage. FASEB J 22(2):590-602 (Pubitemid 351225595)
88. Saunders EC, DE Souza DP, Naderer T, Sernee MF, Ralton JE, Doyle MA, Macrae JI, Chambers JL, Heng J, Nahid A, Likic VA, McConville MJ (2010) Central carbon metabolism of Leishmania parasites. Parasitology 137(9):1303-1313
89. Chen M, Zhai L, Christensen SB, Theander TG, Kharazmi A (2001) Inhibition of fumarate reductase in Leishmania major and L. donovani by chalcones. Antimicrob Agents Chemother 45(7):2023-2029 (Pubitemid 32591693)
90. Carvalho L, Luque-Ortega JR, López-Martín C, Castanys S, Rivas L, Gamarro F (2011) The 8-aminoquinoline analogue sitamaquine causes oxidative stress in Leishmania donovani promastigotes by targeting succinate dehydrogenase. Antimicrob Agents Chemother 55(9):4204-4421